Payment overview · 2025
General Payments
$260.06
14 reported records · 7 companies
Healthcare provider profile · identity verified
Peter Stathopoulos, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STATEN ISLAND, NY · NPI 1265405161
Verified facts
What the public records show
CMS Open Payments records show Peter Stathopoulos, M.D. received $260.06 in general payments during 2025 across 14 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.03 | 29.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.64 | 19.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.34 | 17.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.41 | 14.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.97 | 6.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.72 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.95 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $241.21 | 13 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $115.21 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.34 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $46.34 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 188 |
| Losartan Potassium | Losartan Potassium | 517 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 470 | 135 |
| Metoprolol Succinate | Metoprolol Succinate | 435 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 416 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 116 |
| Hydrochlorothiazide | Hydrochlorothiazide | 281 | 80 |
| Omeprazole | Omeprazole | 221 | 67 |
| Alprazolam | Alprazolam | 207 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 67 |
| Metformin Hcl | Metformin Hcl | 201 | 57 |
| Simvastatin | Simvastatin | 181 | 59 |
| Metformin Hcl Er | Metformin Hcl | 155 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 152 | 44 |
| Furosemide | Furosemide | 141 | 43 |
| Lisinopril | Lisinopril | 138 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 34 |
| Azithromycin | Azithromycin | 132 | 84 |
| Eliquis | Apixaban | 120 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 37 |
| Famotidine | Famotidine | 110 | 32 |
| Meloxicam | Meloxicam | 105 | 31 |
| Gabapentin | Gabapentin | 101 | 30 |
| Prednisone | Prednisone | 99 | 46 |
| Nifedipine Er | Nifedipine | 97 | 25 |
| Enalapril Maleate | Enalapril Maleate | 95 | 31 |
| Jardiance | Empagliflozin | 92 | 22 |
| Ibuprofen | Ibuprofen | 84 | 17 |
| Sertraline Hcl | Sertraline Hcl | 82 | 23 |
| Allopurinol | Allopurinol | 78 | 21 |
| Alendronate Sodium | Alendronate Sodium | 72 | 19 |
| Ozempic | Semaglutide | 72 | 17 |
| Synthroid | Levothyroxine Sodium | 72 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 70 | 16 |
| Atenolol | Atenolol | 69 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 18 |
| Potassium Chloride | Potassium Chloride | 66 | 22 |
| Levofloxacin | Levofloxacin | 63 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 16 |
| Valsartan | Valsartan | 58 | 17 |
| Ezetimibe | Ezetimibe | 57 | 20 |
| Montelukast Sodium | Montelukast Sodium | 57 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 56 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 53 | 26 |
| Ramipril | Ramipril | 51 | 14 |
| Tramadol Hcl | Tramadol Hcl | 49 | suppressed |
| Dexamethasone | Dexamethasone | 44 | 36 |
| Donepezil Hcl | Donepezil Hcl | 44 | 14 |
| Finasteride | Finasteride | 44 | 13 |
| Glipizide | Glipizide | 43 | 14 |
| Glipizide Er | Glipizide | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 31 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Ketoconazole | Ketoconazole | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 18 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $260.06 · 14 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, AREXVY, AVYCAZ, EMBLAVEO, INSPIRE, JARDIANCE, NURTEC ODT, PAXLOVID, TRELEGY ELLIPTA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error